Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

Novartis130 enrolled

Overview

This study will assess the effectiveness and safety of different combination antihypertensive treatments in patients with severe hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

130

Conditions

Hypertension

Interventions

valsartan/amlodipineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with severe hypertension Exclusion Criteria: * History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm * Liver, kidney, or pancreas disease * Insulin dependent diabetes * Allergy to certain medications used to treat high blood pressure Other protocol-defined inclusion/exclusion criteria may apply.

Locations (1)

Novartis Pharmaceuticals

East Hanover, New Jersey, United States

Outcomes

Primary Outcomes

Adverse events and serious adverse events at each study visit for 6 weeks

Secondary Outcomes

Sitting and standing blood pressure measurements after 6 weeks

Laboratory test data after 6 weeks

Vital signs at each study visit for 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.